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Stroke is the leading cause of long-term neurological dis-ability and a frequent cause of death worldwide with an 
annual incidence exceeding 10 million and a prevalence of 42 
million.1 The most detrimental type of ischemic stroke due to 
large vessel occlusion accounts for just one-third of its inci-
dence yet represents by far the largest contributor to morbidity 
and mortality.2 Reperfusion by endovascular thrombectomy 
(EVT) has recently transformed care for these patients after 
7 clinical trials demonstrated substantial benefits in reducing 
disability.3–9 EVT has been adopted as standard of care10 and 
has been demonstrated to be cost saving in multiple healthcare 
settings.11–16
The achieved grade of reperfusion after EVT is critical 
in this new era of stroke care. The current American Stroke 
Association guidelines recommend modified Thrombolysis in 
Cerebral Infarction (mTICI) grades of 2b or 3 for EVT, with 
mTICI 2b referring to 50% to 99% reperfusion and mTICI 
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3 to 100% reperfusion.10 However, mTICI 2b is very crude; 
more granular definitions have been introduced. The expanded 
TICI (eTICI) classification adds the eTICI 2c category, which 
marks 90% to 99% reperfusion.17 Importantly, every lesser 
grade of reperfusion affected outcomes and increased mor-
tality in a meta-analysis of 7 trials.18
The major breakthroughs that drove the success of the piv-
otal EVT trials in 2015 were faster treatment, patient selection 
with imaging, and the technical development of third-gener-
ation thrombectomy devices in the form of stent retrievers, 
which significantly increased reperfusion rates and accel-
erated procedures.19 To evaluate the potential of further im-
provement of reperfusion, we sought to define and quantify 
the long-term health and cost consequences of the achieved 
grade of eTICI reperfusion for patients with stroke, healthcare 
systems, and society.
Methods
In support of the Transparency and Openness Promotion Guidelines, 
the authors offer cost calculations for healthcare systems and societ-
ies aside from the United States.20 Requests that provide a country-
specific cost framework are welcomed by the corresponding author. 
All participants of the meta-analysis provided written informed con-
sent according to each trial protocol, and each study was approved by 
the local ethics board. The data that support the findings of this study 
are available from the corresponding author on reasonable request.
Model Structure
We performed quality-adjusted life year (QALY) and cost estimations 
for the United States adopting the healthcare and societal perspective. 
We adhered to the recommendations by the Second Panel on Cost-
Effectiveness in Health and Medicine21 and the Consolidated Health 
Economic Evaluation Reporting Standards22 statement.
A Markov model was developed using decision-analytic software 
(TreeAge Pro 2017, version 17.1.1.0; TreeAge, Williamstown/MA). 
A short-run model was created to analyze costs and functional out-
comes within the initial 90 days after the index stroke. Patients enter 
the model on admission to the hospital for acute ischemic stroke with 
different grades of reperfusion after EVT and afterward enter one of 
the 7 health states according to the degree of disability as assessed by 
the modified Rankin Scale (mRS). The lead analysis was performed 
for a stroke onset at the age of 65 years. The model does not com-
pare the treatments of EVT versus intravenous thrombolysis nor does 
it apply to patients that only receive intravenous thrombolysis. A 
long-run Markov state transition model estimated the expected costs 
and outcomes over the lifetime of the patient, using a cycle length of 
1 year. During each cycle, patients could either remain in the same 
health state, suffer a recurrent stroke and recover or transit to worse 
mRS states, or die. Death resulted from age-related mortality rates 
and the excess mortality rates of stroke survivors. The model struc-
ture is shown in Figure 1 (extended Figure I in the online-only Data 
Supplement). All simulations were carried out over a lifetime horizon 
(detailed Figure II in the online-only Data Supplement).
Model Input Parameters
The input parameters for the model were based on contemporary 
EVT trial collaboration data and the most recently published liter-
ature providing the best available level of evidence (Table 1).14,23–36 
We accounted for the impact of patients’ age on all input parameters 
based on a recent systematic review.15
Probabilities of Clinical Events
The initial probabilities (ie, the probability of entering a specific mRS 
health state at the end of the initial 90 days) were derived from patients 
in the intervention arms of the 7 EVT trials within the HERMES trial 
(Highly Effective Reperfusion evaluated in Multiple Endovascular 
Stroke) collaboration (Figure 2). The probabilities and 95% CIs for 
each mRS level in the subgroups of eTICI reperfusion grading were 
calculated after model adjustment for age, sex, baseline National 
Institutes of Health Stroke Scale, and time from onset to randomi-
zation. The eTICI grades 0 and 1 were merged based on the small 
sample sizes. The transition probabilities during each annual cycle 
of the long-run model accounted for remaining in the same health 
state, the annual recurrent stroke rate, the probability of reentering 
the same or a lower health state following recurrent stroke, and the 
annual death rate. The age-specific annual death rate of the general 
population was drawn from the United States Life Table.25 The excess 
death rate of stroke survivors was calculated according to hazard rates 
by mRS states as reported by contemporary cohort studies.26
Costs
Aside from the cumulative lifetime costs, we also calculated the net 
monetary benefit (NMB) to determine the economic value of care. 
The NMB combines weighted QALYs and costs into one composite 
outcome: NMB=([lifetime QALYs×willingness-to-pay]−lifetime 
costs). A higher NMB indicates a better economic value of care. 
NMBs were calculated using a willingness-to-pay threshold of 
$100 000 per QALY.
For the healthcare perspective, direct costs within the first 
90 days after stroke and direct annual long-term costs were based 
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Figure 1. Structure of the Simulation Model on Reperfusion Grade after endovascular thrombectomy (EVT). Shown is the simulation model used to estimate 
lifetime costs and quality-adjusted life years of patients with stroke with large vessel occlusions depending on the achieved grade of reperfusion after EVT. 
A, Subgroups according to eTICI grading. The blue square indicates the decision node, the point at which reperfusion is decided. In B, the purple encircled 
letter M indicates the Markov node with branches indicating the health states in transition each year. In C, the green circle indicates the chance node, after 
which there is a probability of the occurrence of each event within a cycle, and the red triangle indicates the terminal node, the end of an individual simulation 
in the model, that is, the death of a patient. eTICI indicates expanded Thrombolysis in Cerebral Infarction; and mRS, modified Rankin Scale.
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on contemporary data and stratified for each of the 7 mRS health 
states.14,27 The costs for EVT were taken from a trial conducted in 
the United States.14 All calculations are based on the assumption that 
the EVT costs are similar for each achieved eTICI grade. The costs 
for intravenous thrombolysis were taken from the current National 
Inpatient Sample.28 All costs were adjusted to 2017 United States 
Dollars according to the medical care component of the Consumer 
Price Index36 and discounted by 3% each year in line with current 
recommendations.21 For the societal perspective, we accounted for 
indirect costs caused by stroke, which were assessed based on the 
human capital approach. The amount of the societal losses are meas-
ured based on the lost productivity due to premature mortality in 
patients with stroke, the reduced productivity that is caused by the 
morbidity of stroke survivors, and the costs for informal care given by 
family members.21 The detailed methods for societal cost calculations 
are provided in the online-only Data Supplement.
Utility Values of Health States
Therapy effectiveness was measured using QALY according to cur-
rent recommendations.21 QALYs were calculated by multiplying 
years spent in mRS health states by assigned utility weights. Utility 
weights were based on a recent consensus analysis.30,37 Values range 
from 0.0 to 1.0, with 0.0 representing no and 1.0 representing perfect 
quality of life. All QALYs were discounted by 3% each year accord-
ing to current recommendations.21
Sensitivity Analyses
To test the robustness of the model prediction, we conducted probabi-
listic sensitivity analyses, allowing for simultaneous alteration of mul-
tiple model input parameters. All input values in the model were varied 
using distributions that reflect each input parameter’s uncertainty as 
derived from HERMES collaboration outcome data or the literature. 
Table 1. Base-Case Values and Sources of Model Input Parameters
Model Input Base-Case Value* Distribution† Source
Initial probabilities
  For each health state mRS 0-6 of EVT-treated patients 90-day mRS distribution for different 
eTICI grades
Dirichlet HERMES (Figure 2)
Transition probabilities
  Recurrent stroke rate 0.059 (for 1st y) β Pennlert et al24
  Annual death rate 0.013 (for 65 y) β Arias et al25
  Annual death hazard rates for survivors mRS 0/1/2/3/4/5 1.53/1.52/2.17/3.18/4.55/6.55 Log normal Hong et al26
  After recurrent stroke control arm Dirichlet Goyal et al23
Health care costs
  Costs within first 90 days after stroke for mRS 
0/1/2/3/4/5/6 (excluding IVT and EVT)
$7996/$11 038/$17 336/$21 440/ 
$28 729/$34 319/$8067
ɣ Dawson et al27
  Additional cost of IVT treatment $6961 ɣ NIS 201428
  Additional cost of EVT treatment $14 554 ɣ Shireman et al14
  Long-term annual costs after stroke for mRS 0/1/2/3/4/5 $11 245/$11 579/$13 395/$23 009/ 
$46 553/$68 441
ɣ Shireman et al14
  Recurrent stroke hospitalization $23 032 ɣ Chambers et al29
Utilities
  mRS 0/1/2/3/4/5/6 1.00/0.91/0.76/
0.65/0.33/0.00/0.00
β Chaisinanunkul et al30
Societal costs
  Paid workforce productivity
   Average annual earnings of employed population $33 000 (for 65 y) ɣ US Census Bureau 201731
   Population employment rate 0.312 (for 65 y) β US Bureau of Labor 
Statistics 201732
   Relative earnings of stroke survivors 0.825 β Vyas et al33
   Return-to-work after stroke mRS 0/1/2/3/4/5 0.63/0.72/0.49/0.19/0.14/0.00 β Tanaka et al34
  Unpaid domestic productivity
   Informal annual caregiving costs mRS 0–1: $1503 mRS 2–5: $7518 ɣ Hickenbottom et al35
All costs were converted to 2017 USD using the medical care component of the Consumer Price Index.36 eTICI indicates expanded Thrombolysis 
in Cerebral Infarction; EVT, endovascular thrombectomy; HERMES, Highly Effective Reperfusion Evaluated in Multiple Endovascular Stroke Trials; IVT, 
intravenous thrombolysis; mRS, modified Rankin Scale; NIS, National Inpatient Sample; and USD, US dollars.
*The minimum and maximum values for ranges were derived from reported or from calculated 95% CIs with the use of variance estimates as 
available. The complete list is provided in Table I in the online-only Data Supplement.
†The term distribution refers to the type of distribution of the data input, which is used for sampling in each iteration of the Monte Carlo simulations. 
This is applied to reflect the uncertainty that is statistically inherent to the data input, which derives from a certain sample size in the above-mentioned 
studies (referenced in the Source column).
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Distributions were calculated using probability density functions ap-
propriate to each parameter, as shown in Table 1 (sensitivity ranges are 
provided in Table I in the online-only Data Supplement). The proba-
bilistic sensitivity analysis was conducted using 10 000 second order 
Monte Carlo simulation runs. As this analysis accounts for all uncer-
tainties related to the model, the results are reported as median esti-
mates with 95% prediction intervals. As a hypothetical scenario, we 
additionally performed a 1-way sensitivity analysis of the cost-effec-
tiveness comparing eTICI 3 and eTICI 2b reperfusion by adding ex-
cess EVT procedure costs to achieve eTICI 3 reperfusion (Figure III in 
the online-only Data Supplement). External model validation was per-
formed using 1-year longitudinal data as reported by the REVASCAT 
trial (Endovascular Revascularization With Solitaire Device Versus 
Best Medical Therapy in Anterior Circulation Stroke Within 8 Hours)38 
and 2-year longitudinal data as reported by the MR CLEAN trial 
(Multicenter Randomized Clinical Trial of Endovascular Treatment 
for Acute Ischemic Stroke in the Netherlands)39 (Supplementary 
Methods and Figure IV in the online-only Data Supplement). Table II 
in the online-only Data Supplement provides lifetime QALY estimates 
from other published analyses. Checklists are provided in Tables III 
and IV in the online-only Data Supplement.
Estimation of Population-Level Effects
For population-level effect estimation, the most recently reported 
annual rate of EVT-treated patients with stroke in the United States 
population (3.3% of all 692 000 ischemic strokes) was considered to 
extrapolate patient-level results to national estimates.40 We set the 
eTICI 2c/3 reperfusion rate within the HERMES meta-analysis as 
reference and estimated the benefits of 10%-step increases.
Results
Reference Case Analysis
The reference case analysis was conducted over a lifetime ho-
rizon for patients with a large vessel occlusion stroke at 65 
years of age. In the probabilistic sensitivity analysis, lifetime 
QALYs increased for every grade of improved reperfusion 
(median QALYs for eTICI 0/1: 2.62; eTICI 2a: 3.46; eTICI 
2b: 5.42; eTICI 2c: 5.99; eTICI 3: 6.73; Figure 3A). The life-
time healthcare and societal costs decreased for every grade of 
improved reperfusion from eTICI 2a to eTICI 3 (eg, median 
healthcare costs for eTICI 2a: $249 019; eTICI 2b: 231 341; 
eTICI 2c: 225 589; eTICI 3: 220 982; Figure 3B).
The lifetime costs after eTICI 0/1 reperfusion were slightly 
higher than after eTICI 3 reperfusion (Figure 3B) yet, on av-
erage, lower than the other reperfusion grades. This results 
from the considerably shorter life expectancy of patients with 
stroke with eTICI 0/1 reperfusion (Figure 3C), by which less 
costs are accumulated as a consequence. Accounting for costs 
and QALYs simultaneously, the steady increase in the eco-
nomic outcome measure NMB illustrates the additional eco-
nomic value of care that is provided by each higher grade of 
eTICI reperfusion (Figure 3D).
The advantage of achieving eTICI 3 over eTICI 2b reper-
fusion resulted in QALY gains of 1.31 (95% prediction in-
terval: 0.43–2.12). Based on the sample sizes in the eTICI 
subgroups, the 95% prediction intervals of the Monte Carlo 
simulations are relatively wide, yet on average, eTICI 3 re-
perfusion compared with eTICI 2b reperfusion is estimated to 
save $10 327 and $20 224 in healthcare and societal costs per 
patient treated with EVT (Table 2).
The temporal development of cumulative QALYs, func-
tional independence, mortality, healthcare, and societal costs 
within the first 20 years after index stroke are provided in 
Figure II in the online-only Data Supplement.
Population-Level Effect Analysis
Taking a nationwide perspective, a 10% increase in the eTICI 
2c/3 reperfusion rate of all annually EVT-treated patients with 
stroke in the United States is estimated to yield additional 
3656 QALYs and save $21.0 million and $36.8 million for the 
healthcare system and society, respectively (Table 3). A 10% 
increase in the eTICI 2c/3 reperfusion rate would increase the 
economic value of care as measured in the NMB by $387 mil-
lion and $402 million, taking healthcare and societal perspec-
tives, respectively.
Sensitivity Analysis
When comparing eTICI 3 versus eTICI 2b reperfusion, achiev-
ing eTICI 3 reperfusion remained the cost saving (ie, dominant) 
strategy even if additional procedure costs that were needed to 
hypothetically achieve eTICI 3 after initial eTICI 2b reperfu-
sion amounted to $10 000 per patient (Figure III in the online-
only Data Supplement). Achieving eTICI 3 after initial eTICI 
2b reperfusion could hypothetically be considered cost-effec-
tive even if additional procedure costs of $74 000 or $139 000 
were incurred, considering contemporary willingness-to-pay 
thresholds of $50 000/QALY or $100 000/QALY, respectively.
Discussion
We found that each level of improved reperfusion by EVT in the 
treatment of patients with stroke with large vessel occlusions 
within the first 6 hours of symptom onset had a pronounced 
impact on the patients’ lifetime health benefits, the healthcare 
system, and society. We estimated that eTICI 3 over eTICI 2b 
reperfusion gains patients around 1.3 additional QALYs and 
saves around $10 000 in healthcare and $20 000 in societal costs 
per patient. If the procedure is judged safe and feasible, striving 
for eTICI 3 reperfusion after initial eTICI 2b reperfusion can 
be supported economically irrespective of any extra procedural 
costs that may potentially be generated along the way.
Figure 2. Adjusted 90-day clinical outcome probabilities based on 
HERMES trial (Highly Effective Reperfusion evaluated in Multiple Endovas-
cular Stroke) data. Shown are the 90-day clinical outcome probabilities of 
patients with stroke in the intervention arms of the 7-trial HERMES collab-
oration stratified by the achieved grade of reperfusion after adjustment for 
age, sex, baseline National Institutes of Health Stroke Scale, and time from 
symptom onset to randomization. The outcomes are scored on the modi-
fied Rankin Scale, with 0 indicating no residual symptoms after stroke and 
6 indicating death as a cause of stroke. eTICI indicates expanded Throm-
bolysis in Cerebral Infarction.
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Enhanced reperfusion rates largely explain the success of 
EVT trials published in 2015 as compared to the 3 preceding 
neutral trials published in 2013.19 In these trials, higher rates 
of reperfusion in the treatment arms were strongly related to 
improved functional outcomes (as demonstrated in Figure 2). 
The prior TIMI (Thrombolysis in Myocardial Infarction) out-
come measure was redefined to the mTICI definition.41,42 The 
recently updated American Stroke Association guidelines pro-
vide a Level I recommendation that defines procedural suc-
cess as mTICI 2b or mTICI 3 reperfusion.10 Several studies, 
however, already demonstrated a significant benefit of mTICI 
3 over mTICI 2b reperfusion.43–45
In addition, emerging evidence supports a redefinition of 
the crude mTICI 2b category, which encompasses 50% to 
99% reperfusion after EVT.46–48 The subclassification, eTICI 
2c reperfusion category, is clearly related to better func-
tional outcomes compared with eTICI 2b.46–48 This renewed 
definition of angiographic success of eTICI 2c and eTICI 3 
has already been adopted as secondary end point in the re-
cently completed ASTER trial (Interest of Direct Aspiration 
First Pass Technique for Thrombectomy Revascularisation 
of Large Vessel Occlusion in Acute Ischaemic Stroke) on 
thrombectomy technique and the ARISE II trial (Analysis 
of Revascularization in Ischemic Stroke With EmboTrap) on 
thrombectomy devices.49,50 Aside from final reperfusion, the 
impact of the first pass effect (first pass eTICI 3 reperfusion), 
which implies faster and more complete reperfusion, has 




Figure 3. Estimated lifetime health benefit and cost savings of successful reperfusion. A, The estimated lifetime quality-adjusted life years (QALYs) for 
patients with stroke depending on the achieved grade of reperfusion. B, The lifetime healthcare costs and societal costs that were achieved per patient. C, 
The life expectancy in years. D, The net monetary benefit per patient from healthcare and societal perspectives. The colored bars indicate the median values 
of the simulations; the error bars indicate the 95% prediction intervals. eTICI indicates expanded Thrombolysis in Cerebral Infarction.
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and should be included in the further testing of new devices 
and techniques.51
Although oftentimes procedural success is limited by indi-
vidual circumstances, secondary improvement of eTICI 2b to 
eTICI 2c/3 reperfusion has been reported to be safe and fea-
sible.52 Importantly, patients with secondary achievement of 
eTICI 2c/3 reperfusion fared equally well as patients with pri-
mary eTICI 2c/3.52 Improved reperfusion leads to health benefits 
and cost savings. Because the estimated annual financial burden 
of stroke in the United States accumulates to $40 billion53 and 
is projected to triple by 2030,54 further improvement in reper-
fusion through procedural strategies or new devices should be 
encouraged by interventionalists and by the medical industry.
How have reperfusion rates improved over recent years, 
and what is the potential in real-world practice outside of tri-
als? Across all first successful EVT trials of 2015 and 2016, 
the meta-analysis of the HERMES collaboration demon-
strated a final reperfusion rate of eTICI 2c/3 of 31.4%.18 In the 
ASTER trial that compared first-line contact aspiration versus 
first-line stent-retriever thrombectomy, the final reperfusion 
rates of eTICI 2c/3 were already 56% for both arms.50 In the 
single-armed ARISE II trial, the final reperfusion of eTICI 
2c/3 was achieved in 76% of patients.49 Single-center experi-
ences outside of clinical trials with new EVT techniques even 
reached final reperfusion eTICI 2c/3 rates of 77% to 80%.55,56
Therefore, further dissemination of procedural experience, 
techniques, and devices bears significant potential to improve 
the outcome of patients with stroke. Given the estimated cost 
savings associated with higher rates of reperfusion in this 
study, financial investments into the training infrastructure, 
the regional availability of experienced interventionalists and 
contemporary EVT devices and assist devices (eg, balloon-
guided catheters) appear justified as they can be expected to 
return investment for the healthcare system and society.
There are limitations of our study that need to be taken 
into account when interpreting the results. First, the cost 
calculations of the lead analysis were performed under the 
assumption that procedural costs are equal for different eTICI 
grades. As procedural success is influenced by a variety of 
known and unknown factors that make it difficult to control 
for, we decided to use this unbiased approach to evaluate the 
implied cost consequences. Furthermore, the procedure costs 
have an overall minor impact on the lifetime financial burden 
of ischemic stroke, as shown in sensitivity analysis. Second, 
the outcome data used for model simulations in this study 
did not arise under the premise of chasing full reperfusion if 
initial reperfusion was adequate. Therefore, safety and feasi-
bility have to be addressed in separate studies. Third, the cost 
calculations were conducted in the United States and the ab-
solute amount cannot be converted to other countries. It has 
to be kept in mind that United States healthcare expenditures 
surpass other countries considerably and that the magnitude 
of cost savings is likely different.57 Yet, the overall findings 
of cost savings associated with improved reperfusion may be 
Table 2. Lifetime Health and Cost Benefit of Successful Reperfusion
Individual Patient-Level Effects (Median Estimates with 95% Prediction Intervals)
Reperfusion Grade Δ QALY
Healthcare Perspective Societal Perspective
Δ Cost ($) Δ NMB ($) Δ Cost ($) Δ NMB ($)
eTICI 2b Reference* Reference* Reference* Reference* Reference*
eTICI 2c +0.57 (0.01 to 1.16) −5.6K (−24K to 12K) +63K (−5.8K to 131K) −9.4K (−30K to 10K) +68K (−4.1K to 137K)
eTICI 3 +1.31 (0.43 to 2.12) −10.3K (−36K to 15K) +142K (41K to 234K) −20K (−48K to 7K) +151K (49K to 244K)
Positive ΔQALY values indicate additional QALYs compared with eTICI 2b. Negative ΔCost values indicate cost savings; positive ΔNMB values indicate higher 
economic value of care compared with eTICI 2b. eTICI indicates expanded Thrombolysis in Cerebral Infarction; K, thousand; NMB, net monetary benefit; and QALY, 
quality-adjusted life year.
*eTICI 2b was set as the reference point for comparisons of eTICI 2c and eTICI 3. eTICI 2b was selected to reflect the minimum procedural recommendation provided 
by the 2018 American Stroke Association guideline.
Table 3. National Public Health and Cost Benefits of Successful Reperfusion
Annual Population-Level Effects in the United States (Median Estimates)
Rate of eTICI 2c/3 Reperfusion Δ QALY
Healthcare Perspective Societal Perspective
Δ Costs ($) Δ NMB ($) Δ Costs ($) Δ NMB ($)
31.4% (HERMES) Reference* Reference* Reference* Reference* Reference*
41.4% (+10%) +3656 −21.0M +387M −36.8M +402M
51.4% (+20%) +7299 −41.8M +772M −73.5M +803M
61.4% (+30%) +10 941 −62.7M +1157M −110.2M +1204M
71.4% (+40%) +14 583 −84.0M +1542M −147.0M +1605M
81.4% (+50%) +18 225 −104.5M +1927M −183.7M +2006M
Positive ΔQALY values indicate additional QALYs compared with the HERMES rate of eTICI 2c/3 reperfusion. Negative ΔCost values indicate cost savings; positive 
ΔNMB values indicate higher economic value of care. eTICI indicates expanded Thrombolysis in Cerebral Infarction; HERMES, Highly Effective Reperfusion Across 
Multiple Endovascular Stroke trials; M, million; NMB, net monetary benefit; and QALY quality-adjusted life year.
*The reperfusion rate in HERMES was arbitrarily set as the reference point for comparisons.
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assumed for other care settings; the authors welcome requests 
providing country-specific cost frameworks and offer calcula-
tions of estimated cost savings for other healthcare systems.
In conclusion, improved reperfusion after EVT grants 
patients with stroke additional QALYs and saves healthcare 
and societal costs. Procedural strategies and device develop-
ment to achieve complete reperfusion (eTICI 3) will be cost 
saving and are justified to harness the full potential of EVT for 
patients with stroke with large vessel occlusions.
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